Syneos Health

Syneos Health, Inc. engages in the provision of outsourced clinical development and commercialization services to biopharmaceutical companies. It operates through the following business segments: Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers clinical development services spanning Phase I to Phase IV, including global studies, as well as unbundled service offerings such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with their drug development process. The Commercial Solutions segment provides commercialization services, including outsourced field selling solutions, medication adherence, communications, and consulting services. The company was founded in 1998 and is headquartered in Morrisville, NC.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q1 2024

Syneos Health reports mixed Q4 results, focuses on growth strategies

Syneos Health's Q4 performance showed mixed results with revenue decline but growth on a constant currency basis. The company is focused on enhancing its operating model, customer engagement, and winning new business opportunities.
Challenges include evaluating spending by large pharma customers and the need for cost structure realignment. However, opportunities lie in engaging with analysts, driving cost savings, and expecting larger pharma awards in 2023.
Overall, Syneos Health remains confident in its strategy, investments, and ability to drive growth in Clinical. The company is navigating challenges while leveraging strengths in customer relationships and value-based pricing.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. We bring together approximately 24,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients.

A Relative Strength Rating upgrade for Syneos Health shows improving technical performance. Will it continue?

Syneos Health Shows Improved Relative Price Performance; Still Shy Of Benchmark

MORRISVILLE, N.C., Sept.  09, 2020  (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), today announced that the Company’s presentation at the Baird 2020 Global Healthcare Conference has been rescheduled because of technical issues. Chief Executive Officer Alistair Macdonald and Chief Financial Officer Jason Meggs will now present today at 12:15 p.m. ET. 

Update:  Syneos Health to Present at the Baird 2020 Global Healthcare Conference at 12:15 p.m. ET Today

Syneos Health (SYNH) reported earnings 30 days ago. What's next for the stock?

Syneos Health (SYNH) Down 8.2% Since Last Earnings Report: Can It Rebound?

MORRISVILLE, N.C., Sept.  02, 2020  (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), today announced that Chief Executive Officer Alistair Macdonald and Chief Financial Officer Jason Meggs are scheduled to present at the Baird 2020 Global Healthcare conference on September 9, 2020, at 8:30 a.m. ET.

Syneos Health to Present at the Baird 2020 Global Healthcare Conference

Syneos Health (SYNH) inks deal with Idorsia to commercialize the treatment for insomnia in the United States.

Syneos Health-Idorsia Collaborate to Launch Daridorexant in US

Idorsia selects Syneos Health as commercialization partner to launch daridorexant in the United States

Syneos Health (SYNH) wins 35 COVID-19 related projects through the second quarter.

Syneos Health (SYNH) Q2 Earnings Top Estimates, Margins Down

Syneos Health, Inc. (SYNH) CEO Alistair Macdonald on Q2 2020 Results - Earnings Call Transcript

Syneos Health (SYNH) delivered earnings and revenue surprises of 20.83% and 0.92%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Syneos Health (SYNH) Q2 Earnings and Revenues Surpass Estimates

Syneos Health Reports Second Quarter 2020 Results

Veeva Systems

BARCELONA, Spain--(BUSINESS WIRE)--Syneos Health is offering biopharmaceutical customers Veeva Commercial Cloud solutions.

Syneos Health Strengthens Commercial Services With Veeva Commercial Cloud

Syneos Health: A Stable CRO With A Strategic COVID-19 Plan

DUBLIN--(BUSINESS WIRE)--The "The Overview of Japanese CSO market ver. 2020" report has been added to ResearchAndMarkets.com's offering.

Overview of the Japanese CSO Market 2020 - Featuring IQVIA Services Japan, Syneos Health Commercial, EPS Holdings, M3 Marketing, and Cimic Ashfield - ResearchAndMarkets.com

MORRISVILLE, N.C., July  13, 2020  (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that it has signed a new three-year agreement with Pfizer Inc. (NYSE: PFE) to deliver global product development solutions to support Pfizer's portfolio. Under the terms of the agreement, Pfizer has the right to extend the term for up to an additional two years. Financial details of the agreement were not disclosed.

Syneos Health Signs New Service Agreement With Pfizer

Acceleron Pharma

Continental Resources

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it.

Notable Insider Buys: Acceleron, Continental And Syneos Health

Tim Pantello Appointed to Lead One of the World’s Largest Healthcare-Only Agency Portfolios

Syneos Health Bolsters Communications Leadership Team

MORRISVILLE, N.C., July  01, 2020  (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its second quarter 2020 financial results on Thursday, August 6, 2020, prior to its earnings call at 8:00 a.m. ET. 

Syneos Health Schedules Second Quarter 2020 Earnings Call for Thursday, August 6, 2020

Syneos Health (SYNH) Up 9.3% Since Last Earnings Report: Can It Continue?

The coronavirus impact results in inaccessibility of several of Syneos Health's (SYNH) clinical trial sites.

Syneos Health (SYNH) Tops Q1 Earnings Estimates, Margins Down

Syneos Health, Inc. (SYNH) CEO Alistair Macdonald on Q1 2020 Results - Earnings Call Transcript

Syneos Health (SYNH) delivered earnings and revenue surprises of 9.68% and 2.05%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Syneos Health (SYNH) Beats Q1 Earnings and Revenue Estimates

Company Expects Aggregate First Quarter Results to  Be in Line With Previously Issued Guidance Range

Syneos Health Provides COVID-19 Business Update

Alongside ACRO, Syneos Health to Provide Support for COVID-19 Testing Centers;  Company Continues Public Service Educational Program to Address Ventilator Shortage 

Syneos Health Responds to COVID-19 Public Health Challenge by Joining Call to Action to Activate Clinically-Qualified Healthcare Professionals

The primary aim of this initiative by Syneos Health (SYNH) is to address the predicted ventilator deficiency in the wake of the coronavirus pandemic.

Syneos Health Launches Initiative for COVID-19 Patients

www.COVID-BiPAPInfo.com    Provides Practical Information for Physicians on Innovative Use of BiPAP Machines – Already Available in Many Hospitals – to Potentially Delay or Remove Need for Mechanical Ventilation for Appropriate COVID-19 Patients

News for Syneos Health Stock (SYNH)